Notice Number: NOT-DA-17-001

Key Dates
Release Date: November 17, 2016

Estimated Publication Date of Announcement: January 2017
First Estimated Application Due Date: February 2017
Earliest Estimated Award Date: December 2017
Earliest Estimated Start Date: December 2017

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The National Institute on Drug Abuse (NIDA) intends to reissue Funding Opportunity Announcement (FOA) PA-13-338 "Neuroscience Research on Drug Abuse (R01)" to solicit applications for research on the neurobiological mechanisms underlying substance use disorders (SUDs) with special emphasis on changes that occur during chronic substance use, withdrawal, relapse, and recovery.

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

The FOA is expected to be published in January 2017, with an initial application due date in February 2017.

This FOA will utilize the R01 activity code. Details of the planned FOA are provided below.

Research Initiative Details

This Notice encourages investigators with expertise and insights into the neurobiology underlying SUDs to begin to consider applying in response to this new FOA.

In addition, collaborative investigations combining expertise in neuroanatomy, neurophysiology, cognitive psychology, genetics, bioinformatics, theoretical neuroscience, and other relevant disciplines will be encouraged and these investigators should also begin considering applying for this application.

Among the areas of research encouraged in this initiative are basic, translational, or clinical research examining the mechanisms that underlie the effects of substance use and SUDs, as well as research designed to improve the translation of existing knowledge of strategies for the prevention and treatment of SUDs.

APPLICATIONS ARE NOT BEING SOLICITED AT THIS TIME.

Inquiries

Please direct all inquiries to:

Roger Sorensen, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301- 443-3205
Email: [email protected]